Skip to main content
Erschienen in: Familial Cancer 2/2010

01.06.2010

Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer

verfasst von: Anna Isinger Ekstrand, Mats Jönsson, Annika Lindblom, Åke Borg, Mef Nilbert

Erschienen in: Familial Cancer | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

The phosphatidylinositol 3-kinases-AKT-mammalian target of rapamycin pathway (PI3K/AKT/mTOR) is central in colorectal tumors. Data on its role in hereditary cancers are, however, scarce and we therefore characterized mutations in PIK3CA and KRAS, and expression of PIK3CA, phosphorylated AKT, and PTEN in colorectal cancers linked to hereditary nonpolyposis colorectal cancer (HNPCC). Sequencing was used to identify mutations in PIK3CA, a real-time PCR-based method to identify KRAS mutations, and immunohistochemical staining was used to evaluate the expression of PIK3CA, phosphorylated AKT and PTEN in 58 HNPCC-associated colorectal cancers. Derangements of at least one of the PI3K/AKT/mTOR components analyzed were found in 51/58 (88%) tumors. Mutations in PIK3CA and KRAS were identified in 14 and 31% of the tumors respectively. Overexpression of PIK3CA and phosphorylated AKT occurred in 59 and 75% and were strongly associated (P = 0.005). Reduced/lost PTEN expression was found in 63% of the tumors. Though HNPCC-associated colorectal cancers show simple genetic profiles with few chromosomal alterations, we demonstrate frequent and repeated targeting of the PI3K/AKT/mTOR pathway, which suggests that therapeutic strategies directed at this pathway are likely to be beneficial also in HNPCC.
Literatur
1.
Zurück zum Zitat Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501CrossRefPubMed Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501CrossRefPubMed
2.
Zurück zum Zitat Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96(8):4240–4245CrossRefPubMed Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96(8):4240–4245CrossRefPubMed
3.
Zurück zum Zitat Cantrell DA (2001) Phosphoinositide 3-kinase signalling pathways. J Cell Sci 114(Pt 8):1439–1445PubMed Cantrell DA (2001) Phosphoinositide 3-kinase signalling pathways. J Cell Sci 114(Pt 8):1439–1445PubMed
4.
Zurück zum Zitat Miyaki M, Iijima T, Yamaguchi T et al (2007) Mutations of the PIK3CA gene in hereditary colorectal cancers. Int J Cancer 121(7):1627–1630CrossRefPubMed Miyaki M, Iijima T, Yamaguchi T et al (2007) Mutations of the PIK3CA gene in hereditary colorectal cancers. Int J Cancer 121(7):1627–1630CrossRefPubMed
5.
Zurück zum Zitat Ollikainen M, Gylling A, Puputti M et al (2007) Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 121(4):915–920CrossRefPubMed Ollikainen M, Gylling A, Puputti M et al (2007) Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 121(4):915–920CrossRefPubMed
6.
Zurück zum Zitat Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554CrossRefPubMed Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554CrossRefPubMed
7.
Zurück zum Zitat Velho S, Oliveira C, Ferreira A et al (2005) The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41(11):1649–1654CrossRefPubMed Velho S, Oliveira C, Ferreira A et al (2005) The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41(11):1649–1654CrossRefPubMed
8.
Zurück zum Zitat Sartore-Bianchi A, Martini M, Molinari F et al (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69(5):1851–1857CrossRefPubMed Sartore-Bianchi A, Martini M, Molinari F et al (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69(5):1851–1857CrossRefPubMed
9.
Zurück zum Zitat Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50(1):113–130CrossRefPubMed Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50(1):113–130CrossRefPubMed
10.
Zurück zum Zitat Allen BA, Terdiman JP (2003) Hereditary polyposis syndromes and hereditary non-polyposis colorectal cancer. Best Pract Res Clin Gastroenterol 17(2):237–258CrossRefPubMed Allen BA, Terdiman JP (2003) Hereditary polyposis syndromes and hereditary non-polyposis colorectal cancer. Best Pract Res Clin Gastroenterol 17(2):237–258CrossRefPubMed
11.
Zurück zum Zitat Peltomaki P, Lothe RA, Aaltonen LA et al (1993) Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 53(24):5853–5855PubMed Peltomaki P, Lothe RA, Aaltonen LA et al (1993) Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 53(24):5853–5855PubMed
12.
Zurück zum Zitat Peltomaki P, Vasen H (2004) Mutations associated with HNPCC predisposition—update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20(4–5):269–276PubMed Peltomaki P, Vasen H (2004) Mutations associated with HNPCC predisposition—update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20(4–5):269–276PubMed
13.
Zurück zum Zitat Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116(6):1453–1456CrossRefPubMed Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116(6):1453–1456CrossRefPubMed
14.
Zurück zum Zitat Ogino S, Goel A (2008) Molecular classification and correlates in colorectal cancer. J Mol Diagn 10(1):13–27CrossRefPubMed Ogino S, Goel A (2008) Molecular classification and correlates in colorectal cancer. J Mol Diagn 10(1):13–27CrossRefPubMed
15.
Zurück zum Zitat Isinger A, Bhat M, Borg A et al (2006) CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum. BMC Cancer 6:64CrossRefPubMed Isinger A, Bhat M, Borg A et al (2006) CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum. BMC Cancer 6:64CrossRefPubMed
16.
Zurück zum Zitat Saal LH, Holm K, Maurer M et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65(7):2554–2559CrossRefPubMed Saal LH, Holm K, Maurer M et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65(7):2554–2559CrossRefPubMed
17.
Zurück zum Zitat Kato S, Iida S, Higuchi T et al (2007) PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 121(8):1771–1778CrossRefPubMed Kato S, Iida S, Higuchi T et al (2007) PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 121(8):1771–1778CrossRefPubMed
18.
Zurück zum Zitat Parsons DW, Wang TL, Samuels Y et al (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436(7052):792CrossRefPubMed Parsons DW, Wang TL, Samuels Y et al (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436(7052):792CrossRefPubMed
19.
Zurück zum Zitat Oda K, Stokoe D, Taketani Y et al (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65(23):10669–10673CrossRefPubMed Oda K, Stokoe D, Taketani Y et al (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65(23):10669–10673CrossRefPubMed
20.
Zurück zum Zitat Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497–5510CrossRefPubMed Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497–5510CrossRefPubMed
21.
Zurück zum Zitat Ikenoue T, Kanai F, Hikiba Y et al (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65(11):4562–4567CrossRefPubMed Ikenoue T, Kanai F, Hikiba Y et al (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65(11):4562–4567CrossRefPubMed
22.
Zurück zum Zitat Samuels Y, Diaz LA Jr, Schmidt-Kittler O et al (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561–573CrossRefPubMed Samuels Y, Diaz LA Jr, Schmidt-Kittler O et al (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561–573CrossRefPubMed
23.
Zurück zum Zitat Fenic I, Steger K, Gruber C et al (2007) Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol Rep 18(1):253–259PubMed Fenic I, Steger K, Gruber C et al (2007) Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol Rep 18(1):253–259PubMed
24.
Zurück zum Zitat Wang Y, Kristensen GB, Helland A et al (2005) Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol 124(3):392–401CrossRefPubMed Wang Y, Kristensen GB, Helland A et al (2005) Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol 124(3):392–401CrossRefPubMed
25.
Zurück zum Zitat Bader AG, Kang S, Vogt PK (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103(5):1475–1479CrossRefPubMed Bader AG, Kang S, Vogt PK (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103(5):1475–1479CrossRefPubMed
26.
Zurück zum Zitat Isakoff SJ, Engelman JA, Irie HY et al (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65(23):10992–11000CrossRefPubMed Isakoff SJ, Engelman JA, Irie HY et al (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65(23):10992–11000CrossRefPubMed
27.
Zurück zum Zitat Zhao JJ, Liu Z, Wang L et al (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102(51):18443–18448CrossRefPubMed Zhao JJ, Liu Z, Wang L et al (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102(51):18443–18448CrossRefPubMed
28.
Zurück zum Zitat Nosho K, Kawasaki T, Ohnishi M et al (2008) PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10(6):534–541PubMed Nosho K, Kawasaki T, Ohnishi M et al (2008) PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10(6):534–541PubMed
Metadaten
Titel
Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer
verfasst von
Anna Isinger Ekstrand
Mats Jönsson
Annika Lindblom
Åke Borg
Mef Nilbert
Publikationsdatum
01.06.2010
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2010
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9293-1

Weitere Artikel der Ausgabe 2/2010

Familial Cancer 2/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.